Ruthenium Complex HB324 Induces Apoptosis via Mitochondrial Pathway with an Upregulation of Harakiri and Overcomes Cisplatin Resistance in Neuroblastoma Cells In Vitro.
Harakiri
apoptosis
cancer chemotherapy
leukemia
lymphoma
mitochondrial pathway
multidrug resistance
neuroblastoma
ruthenium
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
04 Jan 2023
04 Jan 2023
Historique:
received:
22
11
2022
revised:
28
12
2022
accepted:
31
12
2022
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Ruthenium(II) complexes with N-heterocyclic carbene (NHC) ligands have recently attracted attention as novel chemotherapeutic agents. The complex HB324 was intensively studied as an apoptosis-inducing compound in resistant cell lines. HB324 induced apoptosis via mitochondrial pathways. Of particular interest is the upregulation of the Harakiri resistance protein, which inhibits the anti-apoptotic and death repressor proteins Bcl-2 (B-cell lymphoma 2) and BCL-xL (B-cell lymphoma-extra large). Moreover, HB324 showed synergistic activity with various established anticancer drugs and overcame resistance in several cell lines, such as neuroblastoma cells. In conclusion, HB324 showed promising potential as a novel anticancer agent in vitro, suggesting further investigations on this and other preclinical ruthenium drug candidates.
Identifiants
pubmed: 36674465
pii: ijms24020952
doi: 10.3390/ijms24020952
pmc: PMC9866957
pii:
doi:
Substances chimiques
Cisplatin
Q20Q21Q62J
Ruthenium
7UI0TKC3U5
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Angew Chem Int Ed Engl. 2021 Sep 1;60(36):19928-19932
pubmed: 34196088
Nat Rev Mol Cell Biol. 2014 Jan;15(1):49-63
pubmed: 24355989
Molecules. 2022 Aug 08;27(15):
pubmed: 35956988
Biomed Pharmacother. 2022 Dec;156:113974
pubmed: 36411649
Medchemcomm. 2017 Dec 20;9(1):173-180
pubmed: 30108911
Cancers (Basel). 2014 Sep 05;6(3):1769-92
pubmed: 25198391
Bioorg Chem. 2020 Nov;104:104193
pubmed: 32947134
BMC Cell Biol. 2013 Jul 09;14:32
pubmed: 23834359
ChemMedChem. 2021 Oct 6;16(19):3017-3026
pubmed: 34196118
J Immunol Methods. 1991 Jun 3;139(2):271-9
pubmed: 1710634
J Med Chem. 2021 Nov 11;64(21):15747-15757
pubmed: 34670090
Apoptosis. 2003 Mar;8(2):115-28
pubmed: 12766472
Chemistry. 2010 Dec 27;16(48):14498-505
pubmed: 20981665
Toxicol Pathol. 2007 Jun;35(4):495-516
pubmed: 17562483
Anat Histol Embryol. 2002 Aug;31(4):214-23
pubmed: 12196263
Int J Biol Sci. 2019 Jul 3;15(8):1755-1770
pubmed: 31360117
Cancer Cell Int. 2015 Jul 15;15:71
pubmed: 26180516
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
Clin Cancer Res. 2004 Jun 1;10(11):3717-27
pubmed: 15173078
Molecules. 2021 Jul 15;26(14):
pubmed: 34299558
Br J Clin Pharmacol. 2017 Dec;83(12):2605-2614
pubmed: 28758697
ChemMedChem. 2011 Dec 9;6(12):2142-5
pubmed: 21901835
Semin Cancer Biol. 2017 Dec;47:57-66
pubmed: 28445781
Nat Biotechnol. 2009 Jul;27(7):659-66
pubmed: 19581876
EMBO J. 1997 Apr 1;16(7):1686-94
pubmed: 9130713
Nature. 2000 Sep 21;407(6802):390-5
pubmed: 11014196
Annu Rev Immunol. 1998;16:395-419
pubmed: 9597135
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Drug Resist Updat. 2004 Apr;7(2):97-110
pubmed: 15158766
ChemMedChem. 2017 Feb 3;12(3):214-225
pubmed: 27997743
Biol Chem. 2014 Oct;395(10):1163-71
pubmed: 25153241
Blood. 2003 May 15;101(10):4098-104
pubmed: 12531810
Anticancer Agents Med Chem. 2015;15(4):408-22
pubmed: 25584691
Nature. 2019 Nov;575(7784):683-687
pubmed: 31748744
Blood. 2001 Mar 1;97(5):1378-87
pubmed: 11222383
J Cell Sci. 2009 Feb 15;122(Pt 4):437-41
pubmed: 19193868
J Cancer Sci Ther. 2019;11(4):
pubmed: 32148661
Mol Biotechnol. 2010 Nov;46(3):308-16
pubmed: 20717753
Med Hypotheses. 2000 Jul;55(1):29-35
pubmed: 11021322
Biochem Soc Trans. 2003 Dec;31(Pt 6):1441-4
pubmed: 14641084
Cancer Res. 1959 May;19(4):359-71
pubmed: 13652119
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
Inorg Chem. 2018 Nov 19;57(22):14427-14434
pubmed: 30406647
Methods Mol Biol. 2013;979:65-70
pubmed: 23397389
Leuk Res. 2011 Mar;35(3):387-93
pubmed: 21131047
Drug Des Devel Ther. 2017 Mar 03;11:599-616
pubmed: 28424538
J Immunol Methods. 1995 Jul 17;184(1):39-51
pubmed: 7622868
Biometals. 2021 Apr;34(2):211-220
pubmed: 33560473
Cell Death Discov. 2019 Feb 8;5:64
pubmed: 30774992
Adv Exp Med Biol. 2015;872:315-33
pubmed: 26216001
Apoptosis. 2000 Nov;5(5):415-8
pubmed: 11256882
Cancer Res. 1999 Apr 1;59(7 Suppl):1693s-1700s
pubmed: 10197582
Dalton Trans. 2013 Feb 7;42(5):1657-66
pubmed: 23149817
Chem Rev. 2014 Apr 23;114(8):4540-63
pubmed: 24456146
Oncogene. 2012 Apr 12;31(15):1869-83
pubmed: 21892204
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Pharmacol Res. 2015 Oct;100:170-4
pubmed: 26276086
Cancer Treat Rev. 2007 Feb;33(1):9-23
pubmed: 17084534
Front Oncol. 2014 May 30;4:128
pubmed: 24910845